{
  "id": 194474,
  "title": "U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1",
  "url": "https://urgent.news/2026/08/05/u-s-fda-approves-takedas-orzeyfultm-oveporexton-the-first-and-only",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-05T22:14:05.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/u-s-fda-approves-takedas-orzeyful-oveporexton-the-first-and-only-medicine-to-treat-the-underlying-cause-of-narcolepsy-type-1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}